Clinical Trial Update: A Study of Orally Administered IPG7236 in Healthy Adult Participants [Phase 1]

View source ↗

Summary

Phase 1 study of oral IPG7236 in healthy adults for atopic dermatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• IPG7236

Snippet

Sponsor: Nanjing Immunophage Biotech Co., Ltd | Conditions: Atopic Dermatitis | Phase 1 | Status: TERMINATED